semaglutide same as wegovy for the Treatment of Chronic Weight Management, US Weight-loss jab could be made

Cardiovascular risk markers normalize

Kailera IPO'd in 2025 with HRS9531 (dual GLP-1/GIP, Phase 3 China readout ~17.7% weight loss February 2026) as its lead asset and HRS-4729 (the triple agonist) as an earlier-stage follow-on

A 2024 phase 2 RCT documented 2.6% hip and 2.1% lumbar spine bone density reductions within 52 weeks at the 1.0 mg semaglutide dose in a specific study population

Its important to remember that while branded medications like Zepbound are FDA-approved, compounded medications are not FDA-approved, though they are provided through FDA-registered and inspected pharmacies

Learn Retatrutide injection timing, meal strategies & side effect management for night shifts and rotating schedules